{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:05:19Z","timestamp":1770062719727,"version":"3.49.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Physiol Biochem"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13105-022-00934-0","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:10:46Z","timestamp":1670317846000},"page":"851-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-4194","authenticated-orcid":false,"given":"Francesca","family":"Terracciani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-130X","authenticated-orcid":false,"given":"Andrea","family":"Falcomat\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-1134","authenticated-orcid":false,"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1138-1967","authenticated-orcid":false,"given":"Umberto","family":"Vespasiani-Gentilucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","volume":"38","author":"AR Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S (2018) Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future. Liver Int 38:47\u201351","journal-title":"Liver Int"},{"issue":"2","key":"934_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol ago 149(2):389\u2013397 (e10)","journal-title":"Gastroenterol ago"},{"issue":"5","key":"934_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis: Dulai et al. Hepatology 65(5):1557\u20131565","journal-title":"Hepatology"},{"issue":"5","key":"934_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatol 61(5):1547\u20131554","journal-title":"Hepatol"},{"issue":"6","key":"934_CR5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM et al (2020) Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol 158(6):1611\u20131625","journal-title":"Gastroenterol"},{"issue":"5","key":"934_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/ijms17050774","volume":"17","author":"L CalzadillaBertot","year":"2016","unstructured":"CalzadillaBertot L, Adams L (2016) The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 17(5):774","journal-title":"Int J Mol Sci"},{"issue":"2","key":"934_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan D, Surabattula R, Wang XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68(2):238\u2013250","journal-title":"J Hepatol"},{"issue":"6","key":"934_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/hep.24268","volume":"53","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R et al (2011) Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatol 53(6):1874\u20131882","journal-title":"Hepatol"},{"issue":"6","key":"934_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R et al (2017) Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67(6):1265\u20131273","journal-title":"J Hepatol"},{"issue":"17","key":"934_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S et al (2021) Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med ott 385(17):1559\u20131569","journal-title":"N Engl J Med ott"},{"issue":"1","key":"934_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","volume":"158","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m H, Talb\u00e4ck M, Andreasson A, Walldius G, Hammar N (2020) Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterol 158(1):200\u2013214","journal-title":"Gastroenterol"},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","volume":"8","author":"LJM Heyens","year":"2021","unstructured":"Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S (2021) Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med 8:615978","journal-title":"Front Med"},{"issue":"5","key":"934_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J et al (2022) Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 71(5):1006\u20131019","journal-title":"Gut"},{"issue":"2","key":"934_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N (2018) Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 68(2):305\u2013315","journal-title":"J Hepatol"},{"issue":"6","key":"934_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.cgh.2018.11.030","volume":"17","author":"H Hagstr\u00f6m","year":"2019","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, St\u00e5l P, Hultcrantz R, Kechagias S (2019) Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 17(6):1148\u20131156 (e4)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"934_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.12647","volume":"46","author":"W Sun","year":"2016","unstructured":"Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y et al (2016) Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study: Non-invasive assessment of liver fibrosis in NAFLD. Hepatol Res 46(9):862\u2013870","journal-title":"Hepatol Res"},{"issue":"9","key":"934_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","volume":"59","author":"S McPherson","year":"2010","unstructured":"McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59(9):1265\u20131269","journal-title":"Gut"},{"issue":"2","key":"934_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM et al (2021) Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 41(2):261\u2013270","journal-title":"Liver Int"},{"key":"934_CR19","doi-asserted-by":"crossref","unstructured":"Patel K, Wilder J (2014) The clinical utility of FibroScan® as a noninvasive diagnostic test for liver disease. Med Devices Evid Res 107","DOI":"10.2147\/MDER.S46943"},{"issue":"8","key":"934_CR20","doi-asserted-by":"publisher","first-page":"e021787","DOI":"10.1136\/bmjopen-2018-021787","volume":"8","author":"W Jiang","year":"2018","unstructured":"Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X et al (2018) Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 8(8):e021787","journal-title":"BMJ Open"},{"issue":"3","key":"934_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H et al (2016) Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterol 150(3):626\u2013637 (e7)","journal-title":"Gastroenterol"},{"issue":"9","key":"934_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/life10090198","volume":"10","author":"MAT Han","year":"2020","unstructured":"Han MAT (2020) Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syndrome. Life 10(9):198","journal-title":"Life"},{"issue":"4","key":"934_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K et al (2019) Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17(4):630\u2013637 (e8)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"934_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","volume":"76","author":"J Boursier","year":"2022","unstructured":"Boursier J, Hagstr\u00f6m H, Ekstedt M, Moreau C, Bonacci M, Cure S et al (2022) Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol 76(5):1013\u20131020","journal-title":"J Hepatol"},{"issue":"5","key":"934_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m H, Talb\u00e4ck M, Andreasson A, Walldius G, Hammar N (2020) Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol 73(5):1023\u20131029","journal-title":"J Hepatol"},{"issue":"3","key":"934_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","volume":"54","author":"K \u00d6nnerhag","year":"2019","unstructured":"\u00d6nnerhag K, Hartman H, Nilsson PM, Lindgren S (2019) Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 54(3):328\u2013334","journal-title":"Scand J Gastroenterol"},{"issue":"43","key":"934_CR27","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.3748\/wjg.v24.i43.4835","volume":"24","author":"U Vespasiani-Gentilucci","year":"2018","unstructured":"Vespasiani-Gentilucci U, Gallo P, Dell\u2019Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A (2018) Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol 24(43):4835\u20134845","journal-title":"World J Gastroenterol"},{"issue":"7","key":"934_CR28","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","volume":"149","author":"R Loomba","year":"2015","unstructured":"Loomba R, Schork N, Chen C-H, Bettencourt R, Bhatt A, Ang B et al (2015) Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterol 149(7):1784\u20131793","journal-title":"Gastroenterol"},{"issue":"12","key":"934_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461\u20131465","journal-title":"Nat Genet"},{"issue":"1","key":"934_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"Y-L Liu","year":"2014","unstructured":"Liu Y-L, Patman GL, Leathart JBS, Piguet A-C, Burt AD, Dufour J-F et al (2014) Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61(1):75\u201381","journal-title":"J Hepatol"},{"issue":"6","key":"934_CR31","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatol 53(6):1883\u20131894","journal-title":"Hepatol"},{"issue":"8","key":"934_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/00365521.2016.1161066","volume":"51","author":"U Vespasiani-Gentilucci","year":"2016","unstructured":"Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L et al (2016) The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 51(8):967\u2013973","journal-title":"Scand J Gastroenterol"},{"key":"934_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/hmg\/ddw341","volume":"13","author":"P Pingitore","year":"2016","unstructured":"Pingitore P, Dongiovanni P, Motta BM, Meroni M, Lepore SM, Mancina RM et al (2016) PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol Genet ott 13:341","journal-title":"Hum Mol Genet ott"},{"key":"934_CR34","first-page":"574","volume":"4","author":"P Pingitore","year":"1841","unstructured":"Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A et al (1841) 2014 Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 4:574\u2013580","journal-title":"Biochim Biophys Acta"},{"key":"934_CR35","doi-asserted-by":"crossref","unstructured":"Wang Y, Kory N, BasuRay S, Cohen JC, Hobbs HH (2019) PNPLA3, CGI\u201058, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatol hep.30583.","DOI":"10.1002\/hep.30583"},{"issue":"15","key":"934_CR36","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","volume":"23","author":"C Pirazzi","year":"2014","unstructured":"Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM et al (2014) PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 23(15):4077\u20134085","journal-title":"Hum Mol Genet"},{"issue":"4","key":"934_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A et al (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46(4):352\u2013356","journal-title":"Nat Genet"},{"issue":"24","key":"934_CR38","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1323785111","volume":"111","author":"H Mahdessian","year":"2014","unstructured":"Mahdessian H, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A et al (2014) TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci 111(24):8913\u20138918","journal-title":"Proc Natl Acad Sci"},{"issue":"20","key":"934_CR39","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","volume":"291","author":"E Smagris","year":"2016","unstructured":"Smagris E, Gilyard S, BasuRay S, Cohen JC, Hobbs HH (2016) Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem 291(20):10659\u201310676","journal-title":"J Biol Chem"},{"issue":"2","key":"934_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","volume":"61","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E et al (2015) Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatol 61(2):506\u2013514","journal-title":"Hepatol"},{"issue":"6","key":"934_CR41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","volume":"65","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Hy\u00f6tyl\u00e4inen T, Leivonen M, Arola J, Orho-Melander M et al (2016) The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 65(6):1263\u20131265","journal-title":"J Hepatol"},{"issue":"12","key":"934_CR42","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ng.3417","volume":"47","author":"S Buch","year":"2015","unstructured":"Buch S, Stickel F, Tr\u00e9po E, Way M, Herrmann A, Nischalke HD et al (2015) A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47(12):1443\u20131448","journal-title":"Nat Genet"},{"issue":"5","key":"934_CR43","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R et al (2016) The MBOAT7-TMC4 variant rs641738 Increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterol 150(5):1219-1230.e6","journal-title":"Gastroenterol"},{"issue":"3","key":"934_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"N Santoro","year":"2012","unstructured":"Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R et al (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatol 55(3):781\u2013789","journal-title":"Hepatol"},{"issue":"2","key":"934_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOL.0000000000000155","volume":"26","author":"A Raimondo","year":"2015","unstructured":"Raimondo A, Rees MG, Gloyn AL (2015) Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr Opin Lipidol 26(2):88\u201395","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"934_CR46","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/hep.30350","volume":"69","author":"Y Ma","year":"2019","unstructured":"Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S et al (2019) 17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease. Hepatol 69(4):1504\u20131519","journal-title":"Hepatol"},{"issue":"1","key":"934_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1194\/jlr.P089953","volume":"60","author":"CJ Pirola","year":"2019","unstructured":"Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Martino J, Gazzi C et al (2019) Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res 60(1):176\u2013185","journal-title":"J Lipid Res"},{"issue":"12","key":"934_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P et al (2018) A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 378(12):1096\u20131106","journal-title":"N Engl J Med"},{"issue":"1","key":"934_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ajhg.2016.05.013","volume":"99","author":"H Shi","year":"2016","unstructured":"Shi H, Kichaev G, Pasaniuc B (2016) Contrasting the Genetic architecture of 30 complex traits from summary association data. Am J Hum Genet 99(1):139\u2013153","journal-title":"Am J Hum Genet"},{"issue":"5","key":"934_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/MPG.0000000000000279","volume":"58","author":"V Nobili","year":"2014","unstructured":"Nobili V, Donati B, Panera N, Vongsakulyanon A, Alisi A, Dallapiccola B et al (2014) A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 58(5):632\u2013636","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"934_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1194\/jlr.P067454","volume":"58","author":"M Krawczyk","year":"2017","unstructured":"Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M et al (2017) Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res 58(1):247\u2013255","journal-title":"J Lipid Res"},{"key":"934_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7564835","volume":"2018","author":"U Vespasiani-Gentilucci","year":"2018","unstructured":"Vespasiani-Gentilucci U, Dell\u2019Unto C, De Vincentis A, Baiocchini A, Delle Monache M, Cecere R et al (2018) Combining genetic variants to improve risk prediction for NAFLD and its progression to cirrhosis: a proof of concept study. Can J Gastroenterol Hepatol 2018:1\u20139","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"934_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","volume":"283","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S et al (2018) Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 283(4):356\u2013370","journal-title":"J Intern Med"},{"issue":"3","key":"934_CR54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/hep.31238","volume":"72","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Stender S (2020) Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatol 72(3):845\u2013856","journal-title":"Hepatol"},{"issue":"4","key":"934_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I et al (2021) Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 74(4):775\u2013782","journal-title":"J Hepatol"},{"issue":"3","key":"934_CR56","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","volume":"20","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, AntonelliIncalzi R, Valenti L et al (2022) A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 20(3):658\u2013673","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"934_CR57","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3945\/ajcn.113.079749","volume":"99","author":"Y-C Lin","year":"2014","unstructured":"Lin Y-C, Chang P-F, Chang M-H, Ni Y-H (2014) Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 99(4):869\u2013874","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"934_CR58","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender S, Kozlitina J, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Hobbs HH, Cohen JC (2017) Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49(6):842\u2013847","journal-title":"Nat Genet"},{"issue":"12","key":"934_CR59","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S (2020) Nonalcoholic steatohepatitis: a review. JAMA 323(12):1175","journal-title":"JAMA"},{"issue":"1","key":"934_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes: HEPATOLOGY, Vol. XX, No. X 2016. Hepatol 64(1):73\u201384","journal-title":"Hepatol"},{"issue":"4","key":"934_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801","journal-title":"J Hepatol"},{"issue":"10","key":"934_CR62","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","volume":"58","author":"M Stepanova","year":"2013","unstructured":"Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z et al (2013) Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 58(10):3017\u20133023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"934_CR63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","volume":"17","author":"M Alexander","year":"2019","unstructured":"Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D et al (2019) Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med 17(1):95","journal-title":"BMC Med"},{"issue":"2","key":"934_CR64","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-serag","year":"2004","unstructured":"El-serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterol 126(2):460\u2013468","journal-title":"Gastroenterol"},{"issue":"2","key":"934_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ajg.2011.327","volume":"107","author":"Y Kawamura","year":"2012","unstructured":"Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T et al (2012) Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107(2):253\u2013261","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"934_CR66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X et al (2020) Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatol 71(3):808\u2013819","journal-title":"Hepatol"},{"key":"934_CR67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2147\/CLEP.S144368","volume":"9","author":"J Simeone","year":"2017","unstructured":"Simeone J, Bae J, Hoogwerf B, Li Q, Haupt A, Ali A et al (2017) Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin. Epidemiol 9:679\u2013688","journal-title":"Clin. Epidemiol"},{"issue":"1","key":"934_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14(1):32\u201342","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"934_CR69","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1210\/er.2008-0009","volume":"29","author":"N Stefan","year":"2008","unstructured":"Stefan N, Kantartzis K, H\u00e4ring H-U (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29(7):939\u2013960","journal-title":"Endocr Rev"},{"issue":"1","key":"934_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2018.0037","volume":"25","author":"J-J Yoo","year":"2019","unstructured":"Yoo J-J, Kim W, Kim MY, Jun DW, Kim SG, Yeon J-E et al (2019) Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 25(1):1\u201311","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"934_CR71","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0016-5085(03)01200-9","volume":"125","author":"GN Ioannou","year":"2003","unstructured":"Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA (2003) Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterol 125(4):1053\u20131059","journal-title":"Gastroenterol"},{"issue":"10","key":"934_CR72","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/gut.2010.213553","volume":"59","author":"M Stepanova","year":"2010","unstructured":"Stepanova M, Rafiq N, Younossi ZM (2010) Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 59(10):1410\u20131415","journal-title":"Gut"},{"issue":"4","key":"934_CR73","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM et al (2020) Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLOS Med 17(4):e1003100","journal-title":"PLOS Med"},{"issue":"1","key":"934_CR74","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","volume":"42","author":"LA Adams","year":"2005","unstructured":"Adams LA, Sanderson S, Lindor KD, Angulo P (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol Gen 42(1):132\u2013138","journal-title":"J Hepatol Gen"},{"issue":"3","key":"934_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41366-021-01015-w","volume":"46","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Mascian\u00e0 G et al (2022) Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes 46(3):486\u2013493","journal-title":"Int J Obes"},{"issue":"4","key":"934_CR76","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10620-012-2446-3","volume":"58","author":"M Otgonsuren","year":"2013","unstructured":"Otgonsuren M, Stepanova M, Gerber L, Younossi ZM (2013) Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci 58(4):1132\u20131140","journal-title":"Dig Dis Sci"},{"issue":"5","key":"934_CR77","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343\u20131351","journal-title":"J Clin Invest"},{"issue":"2","key":"934_CR78","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","volume":"134","author":"E Fabbrini","year":"2008","unstructured":"Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S (2008) Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterol 134(2):424\u2013431","journal-title":"Gastroenterol"},{"issue":"4","key":"934_CR79","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","volume":"48","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48(4):634\u2013642","journal-title":"Diabetologia"},{"issue":"8","key":"934_CR80","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","volume":"65","author":"M Mota","year":"2016","unstructured":"Mota M, Banini BA, Cazanave SC, Sanyal AJ (2016) Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metab 65(8):1049\u20131061","journal-title":"Metab"},{"issue":"8","key":"934_CR81","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2016) Adipokines in nonalcoholic fatty liver disease. Metab 65(8):1062\u20131079","journal-title":"Metab"},{"issue":"01","key":"934_CR82","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1055\/s-0032-1306423","volume":"32","author":"H Chatrath","year":"2012","unstructured":"Chatrath H, Vuppalanchi R, Chalasani N (2012) Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 32(01):022\u2013029","journal-title":"Semin Liver Dis"},{"issue":"5","key":"934_CR83","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"H-K Min","year":"2012","unstructured":"Min H-K, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J et al (2012) Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15(5):665\u2013674","journal-title":"Cell Metab"},{"issue":"1","key":"934_CR84","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","volume":"52","author":"G Musso","year":"2013","unstructured":"Musso G, Gambino R, Cassader M (2013) Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 52(1):175\u2013191","journal-title":"Prog Lipid Res"},{"key":"934_CR85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.12688\/f1000research.21918.1","volume":"9","author":"N M\u00e9ndez-S\u00e1nchez","year":"2020","unstructured":"M\u00e9ndez-S\u00e1nchez N, Cerda-Reyes E, Higuera-de-la-Tijera F, Salas-Garc\u00eda AK, Cabrera-Palma S, Cabrera-\u00c1lvarez G et al (2020) Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Res gen 9:56","journal-title":"F1000Res gen"},{"key":"934_CR86","doi-asserted-by":"crossref","unstructured":"Karadeniz G, Acikgoz S, Tekin IO, Tasc\u00fdlar O, Gun BD, C\u00f6mert M. Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in experimental cholestasis. Clinics [Internet]. 2008 [citato 2022 mag 5];63(4). Available from: http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322008000400020&lng=en&nrm=iso&tlng=en","DOI":"10.1590\/S1807-59322008000400020"},{"issue":"2","key":"934_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/labinvest.2011.159","volume":"92","author":"Furumaki H Yimin","year":"2012","unstructured":"Yimin Furumaki H, Matsuoka S, Sakurai T, Kohanawa M, Zhao S et al (2012) A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. Lab Invest 92(2):265\u2013281","journal-title":"Lab Invest"},{"issue":"1","key":"934_CR88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12950-019-0211-5","volume":"16","author":"C-M Ho","year":"2019","unstructured":"Ho C-M, Ho S-L, Jeng Y-M, Lai Y-S, Chen Y-H, Lu S-C et al (2019) Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. J Inflamm 16(1):7","journal-title":"J Inflamm"},{"issue":"13","key":"934_CR89","doi-asserted-by":"publisher","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","volume":"97","author":"P Golabi","year":"2018","unstructured":"Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM (2018) Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Med (Baltimore) 97(13):e0214","journal-title":"Med (Baltimore)"},{"issue":"3","key":"934_CR90","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","volume":"62","author":"ZM Younossi","year":"2013","unstructured":"Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A (2013) In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metab 62(3):352\u2013360","journal-title":"Metab"},{"issue":"1","key":"934_CR91","first-page":"83","volume":"10","author":"P Portincasa","year":"2021","unstructured":"Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D\u2019Amato M et al (2021) Intestinal barrier and permeability in health, obesity and NAFLD. Biomed 10(1):83","journal-title":"Biomed"},{"issue":"3","key":"934_CR92","doi-asserted-by":"publisher","first-page":"701","DOI":"10.5114\/aoms.2016.58831","volume":"14","author":"U Vespasiani-Gentilucci","year":"2018","unstructured":"Vespasiani-Gentilucci U, Gallo P, Picardi A (2018) The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 14(3):701\u2013706","journal-title":"Arch Med Sci"},{"issue":"7","key":"934_CR93","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","volume":"11","author":"M Raman","year":"2013","unstructured":"Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S et al (2013) Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11(7):868-875.e3","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"934_CR94","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep.26319","volume":"58","author":"M Mouzaki","year":"2013","unstructured":"Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE et al (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatol 58(1):120\u2013127","journal-title":"Hepatol"},{"issue":"6","key":"934_CR95","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","volume":"49","author":"L Miele","year":"2009","unstructured":"Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatol 49(6):1877\u20131887","journal-title":"Hepatol"},{"issue":"7","key":"934_CR96","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","volume":"56","author":"PD Cani","year":"2007","unstructured":"Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761\u20131772","journal-title":"Diabetes"},{"issue":"2","key":"934_CR97","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD et al (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatol 57(2):601\u2013609","journal-title":"Hepatol"},{"issue":"7","key":"934_CR98","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","volume":"13","author":"C Leung","year":"2016","unstructured":"Leung C, Rivera L, Furness JB, Angus PW (2016) The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13(7):412\u2013425","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"934_CR99","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.26030","volume":"57","author":"S Tanwar","year":"2013","unstructured":"Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD et al (2013) Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol Baltim Md 57(1):103\u2013111","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"934_CR100","first-page":"736","volume":"40","author":"MA Karsdal","year":"2020","unstructured":"Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R et al (2020) Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int Off J Int Assoc Study Liver 40(4):736\u2013750","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"3","key":"934_CR101","first-page":"303","volume":"5","author":"MJ Nielsen","year":"2013","unstructured":"Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q et al (2013) The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 5(3):303\u2013315","journal-title":"Am J Transl Res"},{"issue":"1","key":"934_CR102","doi-asserted-by":"publisher","first-page":"S671","DOI":"10.1016\/S0168-8278(17)31812-3","volume":"66","author":"SJ Daniels","year":"2017","unstructured":"Daniels SJ, Nielsen MJ, Krag A, Eslam M, Karsdal MA, Leeming DJ et al (2017) Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver disease. J Hepatol 66(1):S671","journal-title":"J Hepatol"},{"key":"934_CR103","doi-asserted-by":"crossref","unstructured":"Mak AL, Lee J, van Dijk A-M, Vali Y, Aithal GP, Schattenberg JM et al 2021 Systematic review with meta-analysis: diagnostic accuracy of pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease. Biomed 9(12):1920","DOI":"10.3390\/biomedicines9121920"},{"issue":"7","key":"934_CR104","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.2337\/dc18-2578","volume":"42","author":"F Bril","year":"2019","unstructured":"Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J et al (2019) Use of plasma fragments of propeptides of type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes. Diabetes Care 42(7):1348\u20131351","journal-title":"Diabetes Care"},{"issue":"2","key":"934_CR105","first-page":"429","volume":"35","author":"MJ Nielsen","year":"2015","unstructured":"Nielsen MJ, Veidal SS, Karsdal MA, \u00d8rsnes-Leeming DJ, Vainer B, Gardner SD et al (2015) Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int Off J Int Assoc Study Liver 35(2):429\u2013437","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"1\u20132","key":"934_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0009-8981(01)00730-6","volume":"316","author":"KHW Boeker","year":"2002","unstructured":"Boeker KHW, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R (2002) Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta Int J Clin Chem 316(1\u20132):71\u201381","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"3","key":"934_CR107","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1023\/A:1026630129025","volume":"44","author":"KM Walsh","year":"1999","unstructured":"Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ (1999) Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 44(3):624\u2013630","journal-title":"Dig Dis Sci"},{"issue":"3","key":"934_CR108","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000439083","volume":"92","author":"R Abdelaziz","year":"2015","unstructured":"Abdelaziz R, Elbasel M, Esmat S, Essam K, Abdelaaty S (2015) Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: is there a relationship? Digestion 92(3):130\u2013137","journal-title":"Digestion"},{"issue":"2","key":"934_CR109","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","volume":"47","author":"IN Guha","year":"2008","unstructured":"Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatol Baltim Md 47(2):455\u2013460","journal-title":"Hepatol Baltim Md"},{"issue":"2","key":"934_CR110","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali Y, Lee J, Boursier J, Spijker R, L\u00f6ffler J, Verheij J et al (2020) Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 73(2):252\u2013262","journal-title":"J Hepatol"},{"issue":"1","key":"934_CR111","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12876-021-01795-5","volume":"21","author":"D Connoley","year":"2021","unstructured":"Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J et al (2021) The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol 21(1):268","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"934_CR112","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1373\/jalm.2018.027359","volume":"3","author":"J Day","year":"2019","unstructured":"Day J, Patel P, Parkes J, Rosenberg W (2019) Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J Appl Lab Med 3(5):815\u2013826","journal-title":"J Appl Lab Med"},{"issue":"8","key":"934_CR113","doi-asserted-by":"publisher","first-page":"e23937","DOI":"10.1371\/journal.pone.0023937","volume":"6","author":"S Cermelli","year":"2011","unstructured":"Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6(8):e23937","journal-title":"PLoS One"},{"issue":"11","key":"934_CR114","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z et al (2020) A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 5(11):970\u2013985","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"934_CR115","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62(5):1148\u20131155","journal-title":"J Hepatol"},{"issue":"10","key":"934_CR116","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.14621","volume":"47","author":"J Boursier","year":"2018","unstructured":"Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM et al (2018) Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 47(10):1387\u20131396","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"934_CR117","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/liv.14084","volume":"39","author":"K Chuah","year":"2019","unstructured":"Chuah K, Wan Yusoff WNI, Sthaneshwar P, Nik Mustapha NR, Mahadeva S, Chan W (2019) MACK-3 (combination of hoMa, Ast and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Liver Int 39(7):1315\u20131324","journal-title":"Liver Int"},{"key":"934_CR118","unstructured":"Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, et al (2022) Development and validation of a score for fibrotic non-alcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc S1542\u20133565(22)00385\u20138."},{"issue":"3","key":"934_CR119","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3343\/alm.2021.41.3.302","volume":"41","author":"SY Jang","year":"2021","unstructured":"Jang SY, Tak WY, Park SY, Kweon Y-O, Lee YR, Kim G et al (2021) Diagnostic efficacy of serum Mac-2 binding protein glycosylation isomer and other markers for liver fibrosis in non-alcoholic fatty liver diseases. Ann Lab Med 41(3):302\u2013309","journal-title":"Ann Lab Med"},{"key":"934_CR120","doi-asserted-by":"publisher","unstructured":"Nah E, Cho S, Kim S, Kim H, Cho H. Diagnostic performance of Mac\u20102 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J. Clin. Lab. Anal. [Internet]. 2020 ago [citato 2022 mag 6];34(8). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/jcla.23316","DOI":"10.1002\/jcla.23316"},{"issue":"7","key":"934_CR121","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","volume":"50","author":"M Abe","year":"2015","unstructured":"Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K et al (2015) Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol lug 50(7):776\u2013784","journal-title":"J Gastroenterol lug"},{"issue":"1","key":"934_CR122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","volume":"31","author":"S Romeo","year":"2020","unstructured":"Romeo S, Sanyal A, Valenti L (2020) Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab 31(1):35\u201345","journal-title":"Cell Metab"},{"issue":"7","key":"934_CR123","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/liv.14495","volume":"40","author":"Y Seko","year":"2020","unstructured":"Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S et al (2020) Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver Int 40(7):1686\u20131692","journal-title":"Liver Int"},{"issue":"6","key":"934_CR124","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/hep.23927","volume":"52","author":"S Sookoian","year":"2010","unstructured":"Sookoian S, Rosselli MS, Gemma C, Burgue\u00f1o AL, Fern\u00e1ndezGianotti T, Casta\u00f1o GO et al (2010) Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 promoter. Hepatol 52(6):1992\u20132000","journal-title":"Hepatol"},{"issue":"7","key":"934_CR125","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","volume":"66","author":"T Hardy","year":"2017","unstructured":"Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S et al (2017) Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 66(7):1321\u20131328","journal-title":"Gut"},{"issue":"5","key":"934_CR126","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2337\/db18-1193","volume":"68","author":"J Ma","year":"2019","unstructured":"Ma J, Nano J, Ding J, Zheng Y, Hennein R, Liu C et al (2019) A peripheral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease. Diabetes 68(5):1073\u20131083","journal-title":"Diabetes"},{"issue":"6","key":"934_CR127","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.22569","volume":"48","author":"O Cheung","year":"2008","unstructured":"Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW et al (2008) Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatol 48(6):1810\u20131820","journal-title":"Hepatol"},{"issue":"12","key":"934_CR128","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/ijms19123966","volume":"19","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani A (2018) miRNA signature in NAFLD: a turning point for a non-invasive diagnosis. Int J Mol Sci 19(12):3966","journal-title":"Int J Mol Sci"},{"key":"934_CR129","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","volume":"424","author":"H Yamada","year":"2013","unstructured":"Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K et al (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424:99\u2013103","journal-title":"Clin Chim Acta"},{"issue":"10","key":"934_CR130","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1136\/gutjnl-2019-319226","volume":"69","author":"GA Baselli","year":"2020","unstructured":"Baselli GA, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M et al (2020) Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut ott 69(10):1855\u20131866","journal-title":"Gut ott"},{"issue":"5","key":"934_CR131","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","volume":"145","author":"SK Murphy","year":"2013","unstructured":"Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, Abdelmalek MF et al (2013) Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterol 145(5):1076\u20131087","journal-title":"Gastroenterol"},{"issue":"3","key":"934_CR132","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/hep.20838","volume":"42","author":"ZM Younossi","year":"2005","unstructured":"Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL et al (2005) A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatol Baltim Md 42(3):665\u2013674","journal-title":"Hepatol Baltim Md"},{"issue":"1","key":"934_CR133","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/hep.23271","volume":"51","author":"LN Bell","year":"2010","unstructured":"Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M et al (2010) Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatol Baltim Md gen 51(1):111\u2013120","journal-title":"Hepatol Baltim Md gen"},{"issue":"3","key":"934_CR134","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/jgh.12726","volume":"30","author":"Y Yamasaki","year":"2015","unstructured":"Yamasaki Y, Nouso K, Miyahara K, Wada N, Dohi C, Morimoto Y et al (2015) Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis: glycan markers for fatty liver diseases. J Gastroenterol Hepatol 30(3):528\u2013534","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"934_CR135","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/hep4.1188","volume":"2","author":"R Mayo","year":"2018","unstructured":"Mayo R, Crespo J, Mart\u00ednez-Arranz I, Banales JM, Arias M, Minchol\u00e9 I et al (2018) Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts. Hepatol Commun 2(7):807\u2013820","journal-title":"Hepatol Commun"},{"issue":"10","key":"934_CR136","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","volume":"14","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Ore\u0161i\u010d M, Leivonen M, Gopalacharyulu P, Hyysalo J, Arola J et al (2016) Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol 14(10):1463-1472.e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"934_CR137","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F et al (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol ott 145(4):782\u2013789 (e4)","journal-title":"Gastroenterol ott"},{"issue":"8","key":"934_CR138","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/jcm7080219","volume":"7","author":"F Salomone","year":"2018","unstructured":"Salomone F, Micek A, Godos J (2018) Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis. J Clin Med 7(8):219","journal-title":"J Clin Med"},{"issue":"1","key":"934_CR139","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida A, Ruhl CE (2017) Liver fibrosis scores predict liver disease mortality in the United States population: Unalp-Arida and Ruhl. Hepatol 66(1):84\u201395","journal-title":"Hepatol"},{"issue":"9","key":"934_CR140","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","volume":"19","author":"T Gidener","year":"2021","unstructured":"Gidener T, Ahmed OT, Larson JJ, Mara KC, Therneau TM, Venkatesh SK et al (2021) Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol 19(9):1915\u20131924 (e6)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"934_CR141","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta S, Sebastiani G, Vigan\u00f2 M, Ampuero J, Wai-Sun Wong V, Boursier J et al (2021) Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol 19(4):806\u2013815 (e5)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"934_CR142","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/liv.14301","volume":"40","author":"S Shili-Masmoudi","year":"2020","unstructured":"Shili-Masmoudi S, Wong GL, Hiriart J, Liu K, Chermak F, Shu SS et al (2020) Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 40(3):581\u2013589","journal-title":"Liver Int"},{"issue":"2","key":"934_CR143","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/gutjnl-2020-323419","volume":"71","author":"J Trebicka","year":"2022","unstructured":"Trebicka J, Gu W, de Ledinghen V, Aub\u00e9 C, Krag A, Praktiknjo M et al (2022) Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut 71(2):402\u2013414","journal-title":"Gut"},{"issue":"4","key":"934_CR144","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","volume":"18","author":"S Grimaudo","year":"2020","unstructured":"Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Camm\u00e0 C, Di Marco V et al (2020) Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol. Hepatol 18(4):935\u2013944 (e3)","journal-title":"Clin Gastroenterol. Hepatol"},{"issue":"4","key":"934_CR145","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jhep.2017.11.038","volume":"68","author":"PJ Meffert","year":"2018","unstructured":"Meffert PJ, Repp KD, V\u00f6lzke H, Weiss FU, Homuth G, K\u00fchn JP et al (2018) The PNPLA3 SNP rs738409: G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort. J Hepatol 68(4):858\u2013860","journal-title":"J Hepatol"},{"issue":"2","key":"934_CR146","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/jgh.14770","volume":"35","author":"P Sahlman","year":"2020","unstructured":"Sahlman P, Nissinen M, Puukka P, Jula A, Salomaa V, M\u00e4nnist\u00f6 S et al (2020) Genetic and lifestyle risk factors for advanced liver disease among men and women. J Gastroenterol Hepatol 35(2):291\u2013298","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"934_CR147","doi-asserted-by":"publisher","first-page":"100262","DOI":"10.1016\/j.jhepr.2021.100262","volume":"3","author":"F Tavaglione","year":"2021","unstructured":"Tavaglione F, De Vincentis A, Jamialahmadi O, Pujia R, Spagnuolo R, Picardi A et al (2021) Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Rep 3(3):100262","journal-title":"JHEP Rep"},{"issue":"3","key":"934_CR148","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.31032","volume":"71","author":"A Unalp-Arida","year":"2020","unstructured":"Unalp-Arida A, Ruhl CE (2020) Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. Hepatol 71(3):820\u2013834","journal-title":"Hepatol"},{"issue":"5","key":"934_CR149","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cgh.2020.04.058","volume":"19","author":"K Wijarnpreecha","year":"2021","unstructured":"Wijarnpreecha K, Scribani M, Raymond P, Harnois DM, Keaveny AP, Ahmed A et al (2021) PNPLA3 gene polymorphism and liver- and extrahepatic cancer\u2013related mortality in the United States. Clin Gastroenterol Hepatol 19(5):1064\u20131066","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"934_CR150","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.gastha.2022.02.002","volume":"1","author":"MI Elsaid","year":"2022","unstructured":"Elsaid MI, Bridges JFP, Li N, Rustgi VK (2022) Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro Hep Adv 1(3):445\u2013456","journal-title":"Gastro Hep Adv"}],"container-title":["Journal of Physiology and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-022-00934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13105-022-00934-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-022-00934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T10:27:44Z","timestamp":1699525664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13105-022-00934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s13105-022-00934-0","relation":{},"ISSN":["1138-7548","1877-8755"],"issn-type":[{"value":"1138-7548","type":"print"},{"value":"1877-8755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"22 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}